解脱,淋巴功能障碍和星细胞激活在粉样蛋白阳性阿尔茨海默氏症的疾病
Hsin-I Chang1, Shih-Wen Chen1, Shu-Hua Huang2
1Department of Neurology, Cognition and Aging Center, Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No. 123 Ta-Pei Rd., Niau-Sung Dist., Kaohsiung 833401, Taiwan.
Mechanisms of ageing and development
|September 19, 2025
概括
负担驱动阿尔茨海默病 (AD) 的认知衰退. 星细胞激活介导神经退行,而淋巴系统功能障碍对认知的影响最小.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 神经退行性疾病 神经退行性疾病
背景情况:
- 阿尔茨海默病 (AD) 涉及tau病理,神经退行和认知能力下降.
- 淋巴系统功能障碍和星细胞激活可能会在AD中恶化神经退行.
- 研究,淋巴功能和星细胞激活的相互作用对于理解AD进展至关重要.
研究的目的:
- 为了检查tau负担,淋巴功能障碍,星细胞激活和粉样蛋白PET阳性AD患者的认知衰退之间的关系.
- 确定天体细胞激活 (GFAP) 作为tau驱动神经退行症中介者的作用.
- 为了比较淋巴细胞生物标志物和天体细胞激活的区域分布.
主要方法:
- 沿周血管空间 (DTI-ALPS) 的扩散张力图像分析用于评估淋巴功能.
- 血GFAP水平,海马体积,认知评分和[F18]Florzolotau PET成像测量了157名阿尔茨海默病患者和117名对照组.
- 进行了回归和调解分析,以评估生物标志物协会和GFAP的调解作用.
主要成果:
- 陶荷重是认知衰退的主要预测因素;DTI-ALPS显示没有显著的认知关联.
- 血GFAP调解了tau负担和海马缩缩之间的关系,表明星球细胞激活在tau驱动的神经退行中的作用.
- 区域分析显示了GFAP和DTI-ALPS的不同模式,GFAP与前带皮和中部部区域相关.
结论:
- 负担是AD认知衰退的主要驱动因素.
- 星细胞激活在调解陶诱导的神经退行方面发挥着重要作用.
- 淋巴系统功能障碍似乎对这种AD队列的认知衰退有有限的直接影响.
相关概念视频
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


